In postprandial period, a single dose of vildagliptin lowered plasma glucose levels by enhancing arrest/inhibition of EGP.[43] Alterations in islet function secondary to increased circulating concentrations of active GLP-1 are accompanied with the decreased postprandial glycemic excursion observed in the presence of vildagliptin in T2DM patients.[44] Three phase 2 studies of vildagliptin administration for 12 weeks in T2DM patients have been demonstrated. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.